Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.34 |
| ▸ | CDK2 | P24941 | 3/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | EEF2K | O00418 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3988316 | 1.00 | SIGMAR1 (0.41) | SIGMAR1ADRA2AADRA2BADRA2CCDK5 | |
| SCHEMBL2940094 | 1.00 | SIGMAR1 (0.41) | SIGMAR1ADRA2AADRA2BADRA2CCDK5 | |
| SCHEMBL19450091 | 1.00 | SIGMAR1 (0.41) | SIGMAR1ADRA2AADRA2BADRA2CCDK5 | |
| SCHEMBL2946238 | 1.00 | SIGMAR1 (0.41) | SIGMAR1ADRA2AADRA2BADRA2CCDK5 | |
| SCHEMBL19450166 | 1.00 | SIGMAR1 (0.41) | SIGMAR1ADRA2AADRA2BADRA2CCDK5 | |
| SCHEMBL556889 | 0.98 | SIGMAR1 (0.43) | SIGMAR1ADRA2AADRA2BADRA2CCDK5 | |
| SCHEMBL29460883 | 0.98 | SIGMAR1 (0.43) | SIGMAR1ADRA2AADRA2BADRA2CCDK5 | |
| SCHEMBL29438246 | 0.93 | — | — | |
| SCHEMBL35277 | 0.93 | — | — | |
| SCHEMBL15492457 | 0.86 | CYP11B2 (0.36) | SIGMAR1ADRA2AADRA2BADRA2CCDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544691-B2 | Guanidine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2009-06-09 | — | — | US | claimed |
| EP-1663993-B1 | GUANIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-12 | — | — | EP | claimed |
| US-20070123510-A1 | Guanidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-05-31 | — | — | US | claimed |
| JP-2007504176-A | — | — | 2007-03-01 | — | — | JP | claimed |
| EP-1663993-A1 | GUANIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-06-07 | — | — | EP | claimed |
| WO-2005023781-A1 | GUANIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-03-17 | — | — | WO | claimed |
| US-10988484-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2021-04-27 | — | — | US | disclosed |
| US-20190315772-A1 | GLUCOSE UPTAKE INHIBITORS | KADMON CORP LLC (US) | 2019-10-17 | — | — | US | disclosed |
| US-10273248-B2 | Glucose uptake inhibitors | Kadmon Corportion, LLC (US) | 2019-04-30 | — | — | US | disclosed |
| WO-2017175985-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING SAME | 주식회사 두산 | 2017-10-12 | — | — | WO | disclosed |
| US-7544691-B2 | Guanidine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2009-06-09 | — | — | US | disclosed |
| EP-1663993-B1 | GUANIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-12 | — | — | EP | disclosed |
| US-20070123510-A1 | Guanidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-05-31 | — | — | US | disclosed |
| EP-1663993-A1 | GUANIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005023781-A1 | GUANIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-03-17 | — | — | WO | disclosed |
| EP-0337944-B1 | UREAS | CIBA-GEIGY AG (CH) | 1993-07-28 | — | — | EP | disclosed |
| EP-0337944-A1 | Ureas | CIBA-GEIGY AG (CH) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123510-A1 | Guanidine derivatives | NPFFR1, NPFFR2, OGFR | SIGMAR1 705/4885ADRA2A 381/4885ADRA2B 343/4885 |
| US-10988484-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A2, SLC2A4 | SIGMAR1 3735/4885ADRA2A 3621/4885ADRA2B 3766/4885 |
| US-20190315772-A1 | GLUCOSE UPTAKE INHIBITORS | SLC2A1, SLC2A4, SLC2A2 | SIGMAR1 3504/4885ADRA2A 4436/4885ADRA2B 4422/4885 |
| US-10273248-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A2, SLC2A4 | SIGMAR1 3683/4885ADRA2A 3478/4885ADRA2B 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.